Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients
IRCT20220309054239N1Phase 3Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Urmia University of Medical Sciences. Primary endpoints: Nausea and Vomiting. Started May 2022; status: completed.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on IRCT20220309054239N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220309054239N1.